Upstream Bio
Industry
Inflammation and Allergy
Website
HBM contact
Company status
Private
Upstream Bio, a clinical-stage biotech company advancing new therapies to treat allergy and inflammation, is developing UPB-101, a clinical-stage monoclonal antibody that inhibits the TSLP receptor.
